Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fortrea Holdings Inc. (FTRE) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.
Fortrea Holdings Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – FTRE
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
Fortrea Holdings Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Fortrea Holdings Inc. (FTRE)
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
FTRE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Fortrea Holdings Inc.
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fortrea Holdings Inc. (FTRE) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.
Lost Money on Fortrea Holdings Inc.(FTRE)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
FTRE ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Fortrea Holdings Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / October 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fortrea Holdings Inc. (FTRE) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.
Fortrea Holdings Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - FTRE
NEW YORK, NY / ACCESSWIRE / October 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
NEW YORK, NY / ACCESSWIRE / October 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Reminds Shareholders of an Investigation into Fortrea Holdings Inc. (FTRE) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
